A multinational survey of HS specialists in Europe found that 81% prescribe antibiotics despite expecting poor response and 79% favor earlier biologic initiation.
KT-621 achieved deep STAT6 degradation and strong 4-week EASI and itch reductions, offering a potential new oral option for moderate–severe AD and other Th2 inflammation-driven disease.
Psychiatric comorbidities affect 25% of AD patients. Here, a check list on when to screen, when to refer, and how to prevent accumulated psychological burden in primary care.